Tilmanocept (Tilmanocept)
Overview of Tilmanocept
Tilmanocept is a new chemical entity and a novel radiodiagnostic imaging agent, targeting the radioisotope, technetium-99m to a mannose-binding protein that resides on the surface of dendritic cells and macrophages.it is used for lymphatic mapping with a hand- held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma. The chemical name of tilmanocept is dextran, 3 [(2-aminoethyl)thio]propyl 17-carboxy-10, 13, 16-tris(carboxymethyl)-8-oxo-4-thia-7, 10, 13, 16-tetraazaheptadec-1-yl 3-[[2-[[1-imino-2-(D mannopyranosylthio)ethyl]amino]thio]propyl ether
Indication of Tilmanocept
Tilmanocept is primarily indicated in conditions like Breast cancer, Melanoma, Squamous cell carcinoma.
Contraindication of Tilmanocept
No data regarding the contra indications of Tilmanocept is available.
Side Effects of Tilmanocept
The symptomatic adverse reactions produced by Tilmanocept are more or less tolerable and if they become severe, they can be treated symptomatically, these include injection site pain, injection site irritation.
Precautions of Tilmanocept
Hypersensitivity: Ask patients about prior reactions to drugs, especially dextran or modified forms of dextran. Observe for hypersensitivity signs and symptoms Radiation Risks:Any radiation-emitting product may increase the risk for cancer, especially in pediatric patients. Adhere to the dose recommendations and ensure safe handling to minimize the risk for excessive radiation exposure to either patients or health care workers.